{
"id":"mk19_a_np_q023",
"number":23,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 23",
"stimulus":[
{
"type":"p",
"hlId":"89fba7",
"children":[
"A 73-year-old woman is evaluated during a follow-up visit for stage G4 chronic kidney disease. She reports no uremic symptoms. Medical history is also significant for hypertension. Medications are atenolol, chlorthalidone, cholecalciferol, hydralazine, and nifedipine."
]
},
{
"type":"p",
"hlId":"9ce0f2",
"children":[
"The physical examination, including vital signs, is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a8b027",
"class":"cell text l",
"children":[
"8.7 mg/dL (2.2 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"2bfd48",
"class":"cell text l",
"children":[
"2.0 mg/dL (176.8 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"39ae6a",
"class":"cell text l",
"children":[
"5.4 mg/dL (1.7 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"ca2815",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Parathyroid hormone, serum",
"children":[
"Parathyroid hormone"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"02008f",
"class":"cell text l",
"children":[
"97 pg/mL (97 ng/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"3370f5",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Vitamin D",
"children":[
"25-hydroxyvitamin D"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"30f099",
"class":"cell text l",
"children":[
"60 ng/mL (150 nmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"77db81",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Glomerular filtration rate (GFR), urine",
"children":[
"Estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"20d29c",
"class":"cell text l",
"children":[
"24 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" "
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Calcitriol"
}
},
{
"letter":"B",
"text":{
"__html":"Calcium acetate"
}
},
{
"letter":"C",
"text":{
"__html":"Cinacalcet"
}
},
{
"letter":"D",
"text":{
"__html":"Low phosphate diet"
}
},
{
"letter":"E",
"text":{
"__html":"Sevelamer"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"7c1e2f",
"hvc":true,
"children":[
"In patients with chronic kidney disease and hyperphosphatemia, the initial step in management is a low phosphate diet."
]
},
{
"type":"keypoint",
"hlId":"15846f",
"hvc":true,
"children":[
"In patients with chronic kidney disease who remain hyperphosphatemic following dietary optimization, the next step is addition of a phosphate binder."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"7a14f7",
"children":[
"The most appropriate management is dietary restriction of phosphorus through a low phosphate diet (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). As kidney function declines, the normal homeostasis of calcium and phosphorus levels by the kidney becomes compromised, resulting in alterations in bone mineralization. The term chronic kidney disease-mineral and bone disorder (CKD-MBD) encompasses these changes. Parathyroid hormone (PTH) is the most important regulator of calcium and phosphorus concentrations. PTH stimulates osteoclasts to resorb bone, stimulates hydroxylation of 25-hydroxyvitamin D in the kidneys, and stimulates tubular reabsorption of calcium and induces renal phosphorus excretion. As CKD progresses, rising fibroblast growth factor 23 levels inhibit the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, resulting in lower intestinal absorption of calcium and phosphorus in the gut, contributing to hypocalcemia. Hypocalcemia is a potent stimulus for further increases in PTH levels. Increased PTH levels result in reduced calcium excretion, increased calcium absorption from the gut, increased phosphorus excretion by the kidneys, and activation of osteoclast bone resorption. As CKD progresses, the kidney is unable to compensate for the increased release of phosphorus from bone, and phosphorus levels rise. Disordered calcium and phosphate metabolism lead to several adverse pathologic effects, including vascular calcification, increased risk for cardiovascular events, and the altered-bone physiology of renal osteodystrophy. The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that, in patients with CKD stages G3a to G5, elevated phosphorus levels should be lowered toward the normal range. Treatment options include dietary modifications (phosphorus restriction) alone or in combination with the administration of phosphate binders."
]
},
{
"type":"p",
"hlId":"3cf2df",
"children":[
"KDIGO guidelines recommend against the use of activated vitamin D analogues such as calcitriol (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") in non-dialysis–dependent patients with CKD to avoid the risk of calcium overload; therefore, calcitriol should be avoided in this non-dialysis–dependent patient. These agents are routinely used in dialysis-dependent patients with end-stage kidney disease as CKD-MBD worsens."
]
},
{
"type":"p",
"hlId":"2eafcf",
"children":[
"For patients who remain hyperphosphatemic following dietary optimization, the next step is addition of a phosphate binder. The choice of a phosphate binder, calcium- or non-calcium–based, must be individualized for each patient. Calcium-based binders include calcium carbonate and calcium acetate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"); non-calcium–based binders include sevelamer (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option E"
]
},
") and lanthanum. However, data are lacking to guide clinicians in choosing calcium-based binders."
]
},
{
"type":"p",
"hlId":"323cbc",
"children":[
"Cinacalcet (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), a calcimimetic that decreases PTH levels, is FDA approved for use in patients who are undergoing dialysis but not for use in patients with CKD."
]
}
],
"relatedSection":"mk19_a_np_s12_6_2_5",
"objective":{
"__html":"Manage hyperphosphatemia in chronic kidney disease-mineral and bone disorder."
},
"references":[
[
"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59."
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":10,
"B":10,
"C":5,
"D":34,
"E":42
},
"hlIds":[
"89fba7",
"9ce0f2",
"a462a3",
"1a4da4",
"a8b027",
"f461b2",
"2bfd48",
"a4922e",
"39ae6a",
"ca2815",
"02008f",
"3370f5",
"30f099",
"77db81",
"20d29c",
"cb2b54",
"7c1e2f",
"15846f",
"7a14f7",
"3cf2df",
"2eafcf",
"323cbc"
]
}